contains FSH and LH in a ratio of 3:1 (Duijkers et al., 1993; 1995 Diedrich et al., 1994. Both preparations are intended for the The objective was to demonstrate bioequivalence between treatment of female and male fertility disorders resulting from s.c. and i.m. administration of Humegon ® (FSH/LH ratio inadequate gonadotrophin stimulation of the gonads as well 1:1) and Normegon ® (FSH/LH ratio 3:1). In two randomas for controlled ovarian hyperstimulation in medically assisted ized, single-centre, cross-over studies, 18 healthy volunteers reproduction programmes. on each formulation were assigned to one of the two Urinary gonadotrophins have been used for Ͼ30 years in administration sequences. Subjects were given single doses the treatment of female and male infertility and most of them of one of the above gonadotrophins after endogenous are indicated for i.m. use. As a result of this administration gonadotrophin production had first been suppressed using route and the possible requirements for injections during the high-dose oral contraceptive. Subsequently, rate (C max , weekend and holidays, practical problems may arise such as t max ) and extent (AUC) of absorption of follicle stimulating the necessity for daily visits to the clinic, and the almost hormone (FSH) and luteinizing hormone (LH) were detercontinuous need for specialized assistance of (para-)medical mined for 14 days. For C max and AUC, analysis of variance staff. Consequently, the procedure may be inconvenient for (ANOVA) was performed on log-transformed data and for both patients and hospital staff. Therefore, s.c. self-injection t max ANOVA was performed on ranks. Intramuscular and of gonadotrophin preparations may offer advantages for both s.c. injections of Humegon were bioequivalent with respect the patients (and their partners) and the hospital in terms of to the main pharmacokinetic parameters, being AUC and convenience and workload.
FSH and LH in a ratio of~3:1, Normegon consequently also Fertilization and Assisted Reproduction, Vienna, Austria,  contains FSH and LH in a ratio of 3:1 (Duijkers et al., 1993; 1995 Diedrich et al., 1994 . Both preparations are intended for the The objective was to demonstrate bioequivalence between treatment of female and male fertility disorders resulting from s.c. and i.m. administration of Humegon ® (FSH/LH ratio inadequate gonadotrophin stimulation of the gonads as well 1:1) and Normegon ® (FSH/LH ratio 3:1). In two randomas for controlled ovarian hyperstimulation in medically assisted ized, single-centre, cross-over studies, 18 healthy volunteers reproduction programmes. on each formulation were assigned to one of the two Urinary gonadotrophins have been used for Ͼ30 years in administration sequences. Subjects were given single doses the treatment of female and male infertility and most of them of one of the above gonadotrophins after endogenous are indicated for i.m. use. As a result of this administration gonadotrophin production had first been suppressed using route and the possible requirements for injections during the high-dose oral contraceptive. Subsequently, rate (C max , weekend and holidays, practical problems may arise such as t max ) and extent (AUC) of absorption of follicle stimulating the necessity for daily visits to the clinic, and the almost hormone (FSH) and luteinizing hormone (LH) were detercontinuous need for specialized assistance of (para-)medical mined for 14 days. For C max and AUC, analysis of variance staff. Consequently, the procedure may be inconvenient for (ANOVA) was performed on log-transformed data and for both patients and hospital staff. Therefore, s.c. self-injection t max ANOVA was performed on ranks. Intramuscular and of gonadotrophin preparations may offer advantages for both s.c. injections of Humegon were bioequivalent with respect the patients (and their partners) and the hospital in terms of to the main pharmacokinetic parameters, being AUC and convenience and workload. C max of FSH absorption. Intramuscular and s.c. injections
Until recently, it was believed that urinary gonadotrophins of Normegon were bioequivalent with respect to the AUC could not be injected s.c., since the administration of these of FSH and not bioequivalent with respect to the C max of preparations with relatively high amounts of impurities via FSH. For t max of FSH as well as for most LH variables of this route may induce undesirable local adverse reactions (Le both preparations, bioequivalence could not be be proven Cotonnec et al., 1993) . Although data have been presented due to the high intra-and interindividual variability and/ indicative of an allergic potential of s.c. injected urinary or concentrations being close to the detection limit. Thus, gonadotrophins in a non-homologous animal model (Biffoni the main pharmacokinetic FSH variables after i.m. and et al., 1994) , clinical studies performed so far have indicated s.c. administration of Humegon and Normegon were bioethat the risk of allergic reactions is minimal and they support quivalent.
the safe administration of urinary gonadotrophins via the s.c. Key words: bioequivalence/FSH/human menopausal gonadroute (Saal et al., 1991a,b; Jones and Darne, 1993; Jones et al., otrophin/intramuscular/LH/subcutaneous 1994; Schmoutziguer et al., 1996) . Thus, the bioequivalence issue of s.c. and i.m. administration of gonadotrophins is important in clinical decision making when choosing an administration route for these preparations which will remain Introduction available for an indeterminate period. On day 22 of oral contraceptive treatment, a single dose of Humegon or Normegon was administered by means of either i.m. or Netherlands) was investigated. Each study included 18 healthy volunteers and both studies were performed according to similar study s.c. injection, depending on the treatment allocation. On day 36, the procedure was repeated, but now in a two-way cross-over fashion as protocols at the TNO Nutrition and Food Institute in Zeist (The Netherlands). This number of subjects is considered to have sufficient far as the route of administration was concerned. After each injection regular blood sampling followed for 14 days. All i.m. injections were power to give information on the actual pharmacodynamic and pharmacokinetic response, based on prior experiences in studies with administered in the upper lateral quadrant of the m. gluteus maximus, whereas the s.c. injections were administered in the frontal part of a similar design (Out et al., 1995) . Assignment of subjects to the sequence of i.m. or s.c. injection of the preparations occurred with the thigh. Before entering the study, the following assessments were made: help of randomization lists. In order to reduce variability caused by endogenous release of FSH and LH, all women used during the study medical, gynaecological and drug anamneses were obtained, physical and gynaecological examinations were performed, a pregnancy test period the high-dose combined oral contraceptive Lyndiol ® to suppress endogenous gonadotrophin production. A high-dose combined prewas performed to exclude pregnancy, blood samples were obtained for measurement of FSH and LH immunoactivity as well as for paration was chosen, since it has been demonstrated that low-dose combined oral contraceptives generally do not ensure complete routine blood biochemistry and haematology. With the exception of the pregnancy test and gonadotrophin determinations, the same pituitary inhibition in all subjects (Dericks-Tan et al., 1976) . All subjects gave their written informed consent to participate in the assessments were performed at the post-treatment visit. Compliance to the daily intake of Lyndiol was checked in both studies by means studies and the principles of the revised Declaration of Helsinki were implemented in the study. The studies were approved by the TNO of regular inquiry by the investigators and also by the assessment of FSH and LH serum concentrations on the day prior to Humegon or Medical Ethics Committee and were performed according to Good Clinical Practice.
Normegon injection. An FSH concentration of Ͻ0.5 IU/l immunoactivity was considered to be indicative of full pituitary suppression. Inclusion criteria were: age between 18 and 39 years of age at the time of screening, use of combined oral contraceptives containing
In the Humegon and Normegon study groups blood samples for determination of FSH-and LH-immunoactivities were taken at the ജ30 µg ethinyl oestradiol per day during at least 3 months prior to the study, a history of normal cycles with a mean length of [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] following times related to injection: - 3, 4, 6, 8, 10, 12, 16, 24, 30, 36, 48, 72, 96, 120, 168, 192, 240, 264, 312 and 336 h. days and an intra-individual variation of Ϯ3 days before the use of oral contraceptives, a good physical and mental health, a body weight After blood sampling, the serum was prepared and stored frozen until the assessments. FSH and LH immunoactivities were determined of 50-75 kg and between 80 and 130% of the ideal body weight (adapted from the Metropolitan Life Insurance Company tables), using a commercially available immunofluorometric assay using the time-resolved fluoroimmunoassay technique (Delfia ® ; Wallac Oy, willing to give written informed consent. Exclusion criteria were: a history of, or current, endocrine abnormalities such as hyperprolactinaTurku, Finland). In both studies the following pharmacokinetic variables were assessed: peak serum concentration (C max ), peak serum emia, polycystic ovary disease or absence of ovarian function, contraindications for the use of combined oral contraceptives or time (t max ), and the area under the serum concentration versus time curve (AUC). For non-detectable concentrations a concentration of gonadotrophins, sitting diastolic blood pressure Ͼ90 mmHg and/or a systolic blood pressure Ͼ150 mmHg, chronic cardiovascular, hepatic, zero was assumed, and for missing values the area was calculated from the measurement preceding the missing value to the measurement renal or pulmonary disease, a history (within 12 months) of or current abuse of alcohol or drugs, treatment with gonadotrophin preparations following the missing value.
Comparison of the demographic data at screening was performed within a period of 6 months prior to screening, blood donation within 90 days prior to screening, concomitant use of medication (except by means of a Wilcoxon rank-sum test on the two subject groups. The bioequivalence of the two administration routes was tested for for occasional analgesics), smoking Ͼ10 cigarettes per day, laboratory values indicative of physical illness, and use of investigational drugs the rate of absorption using C max and t max , whereas for the extent of absorption bioequivalence was tested using AUC. For C max and AUC within 3 months prior to screening.
Lyndiol (containing 50 µg ethinyl oestradiol and 2.5 mg lynestrenol an analysis of variance (ANOVA) was performed on the logtransformed values and the 90% confidence intervals (CI) were per tablet; batches 93A04 and CP094072) is a high-dose oral contraceptive preparation. Starting on day 1 of the study, subjects derived from the ratio of the means µ(s.c.)/µ(i.m.). For t max , the ANOVA was performed on ranks and the 90% non-parametric CIs were instructed to take one tablet per day for 50 consecutive days in order to achieve full pituitary suppression before the gonadotrophin were determined using Walsh differences for the true difference between the means µ(s.c.) -µ(i.m.). injections (on days 22 and 36) and subsequently throughout the blood sampling period. Humegon (FSH/LH ratio 1:1, batch CP093153) was For determination of clinically relevant differences acceptance ranges were defined as follows: for the ratio of the means [µ(s.c.)/ supplied as a freeze-dried, lyophilized powder in ampoules containing 75 IU of FSH and 75 IU of LH in-vivo bioactivity, as determined in µ(i.m.)] of C max and AUC, the range from 0.8-1.25 was used and for the true difference between the means [µ(s.c.) -µ(i.m.)] of t max , the ovarian weight augmentation assay (Steelman and Pohley, 1953) and the seminal vesicle weight assay (Van Hell et al., 1964) . For Ϯ20% of the i.m. mean was used. The formulations were declared bioequivalent with respect to a certain parameter if the 90% CI was injection, four ampoules of Humegon (containing in total 300 IU FSH-bioactivity and 300 IU LH-bioactivity) were dissolved in 2 ml fully within the acceptance range for that particular parameter, according to the recommendations of the International Harmonisation solvent. Normegon [(Org 31338) FSH/LH ratio 3:1, batch CP090033] was supplied as a freeze-dried, lyophilized powder in ampoules and Consensus DIA Meeting on bioavailability testing requirements and standards (Cartwright, 1991) . For C max and AUC if the 90% CI containing 75 IU of FSH and 25 IU LH in-vivo bioactivity, as determined in the ovarian weight augmentation assay (Steelman and was within the acceptance range, then bioequivalence was proven; if the value 1 (0 for t max ) was within the 95% CI but the 90% CI was Pohley, 1953) and the seminal vesicle weight assay (Van Hell et al., 1964) . For injection, four ampoules of Normegon (containing in total outside the acceptance range, then bioequivalence was not proven, since the outcome was inconclusive due to large intra-and interindi-300 IU FSH-bioactivity and 100 IU LH-bioactivity) were dissolved in 2 ml solvent. vidual variation; if the value 1 (0 for t max ) was outside the 95% CI and also the 90% CI was outside the acceptance range, then nonbioequivalence was proven. Statistical calculations were performed using SAS version 6.06 under VAX/VMS operating system V5.3.
Results
All subjects in the Humegon study group completed the studies. Of the 18 women randomized in the Normegon study, 15 completed it successfully whereas three subjects discontinued for reasons unrelated to treatment: one woman was excluded after erroneous injection of Humegon instead of Normegon, one subject was discontinued because of the occurrence of an intercurrent bacterial infection requiring antibiotic treatment, and one woman withdrew from the study shortly after starting oral contraceptive treatment. In the years (range 18-26), the mean height was 175.4 Ϯ 6.3 cm (range 158-184) and the mean body weight was 63.9 Ϯ 6.1 kg (range 53-74). In the Normegon study the corresponding figures were 21.6 Ϯ 2.1 years (range 19-26), 175.1 Ϯ 7.4 cm (range 156-186) and 65.9 Ϯ 5.7 kg (range 54-75). Comparison of the average age, height and body weight of the different administration sequences within each study using a Wilcoxon rank-sum test revealed no statistically significant betweensequence differences.
The mean values of the pharmacokinetic parameters obtained during bioequivalence testing of the i.m. and s.c. administration routes of Humegon are presented in Table I . The plots of the mean FSH and LH serum levels per treatment group over time are presented in Figures 1 and 2 respectively. There were neither statistically nor clinically significant differences between the mean AUC 0-336 of FSH for s.c. and i.m. Humegon injection and consequently bioequivalence was proven. For C max of FSH, although the difference between i.m. and s.c. injection was statistically significant, the 90% CI was still within the acceptance range. Therefore, the difference was clinically not have resulted in a stronger suppression of endogenous FSH release during the second period and consequently to lower significant and bioequivalence was still proven. For t max of FSH, although there were no statistically significant betweenresidual serum concentrations. The mean AUC 0-336 of LH seemed to be larger after s.c. group differences, there was a large intra-and interindividual variability with the 90% CI outside the acceptance range.
than after i.m. Humegon injection. Although the difference between the two administration routes was not statistically Consequently, bioequivalence could not be proven. With respect to FSH, for both C max and AUC 0-336 a period effect significant, bioequivalence could not be proven (90% CI outside the acceptance range). The C max was similar for i.m. was found. Subjects receiving Humegon on day 36 had been exposed to the oral contraceptive preparation for 14 days and s.c. injection, since the between-group differences were neither statistically nor clinically significant. Therefore, for longer than subjects receiving Humegon on day 22. This may this parameter bioequivalence was proven. With respect to preparation were reported in most of the subjects. Although t max , absorption seemed to be faster after i.m. than after s.c. both gonadotrophin administration routes caused some irritainjection. Although the between-group difference was not tion and/or pain at the injection site in most of the subjects, statistically significant, bioequivalence could not be proven starting several hours after injection and lasting up to several (90% CI outside the acceptance range). Similar to the findings days, the i.m. as well as the s.c. injections with Humegon and obtained for FSH, with LH a period effect was found for Normegon were well tolerated. C max and AUC 0-336 , resulting in a stronger suppression of endogenous LH release during the second period. Discussion The mean values of the pharmacokinetic parameters used during bioequivalence testing of i.m. and s.c. injection of From the current study it appeared that, in terms of the extent of FSH absorption, as measured by the AUC, the s.c. Normegon are presented in Table II . The plots of the mean FSH and LH serum concentrations per treatment group over administration route for Humegon is bioequivalent with the i.m. route. In addition, bioequivalence could also be proven time are presented in Figures 3 and 4 respectively. For the AUC 0-336 of FSH, although the difference between i.m. and for the rate variable of FSH absorption C max . With respect to LH variables, bioequivalence of the two administration routes s.c. injection was statistically significant, the 90% CI was still within the acceptance range. Therefore, the difference was could be proven for C max . For t max of FSH and LH, bioequivalence could not be proven due to the large intra-and interindiclinically not significant and bioequivalence was proven. For the C max , the two administration routes of Normegon revealed vidual variability. Non-bioequivalence was not proven for a particular variable after i.m. and s.c. Humegon injection. Since statistically significantly different peak plasma concentrations and since the 90% CI was also outside the acceptance range, for follicular development FSH pharmacokinetics are much more important than those of LH, proof of LH bioequivalence it was concluded that the two administration routes were not bioequivalent for C max . For the t max , bioequivalence could not is of little relevance for the efficacy of Humegon. Although a period effect (due to a stronger suppression of endogenous FSH be proven. A period effect was found for the AUC 0-336 of FSH.
Bioequivalence with respect to LH could not be proven for with longer duration of administration of the oral contraceptive preparation) for both C max and AUC of FSH and LH was any of the investigated pharmacokinetic parameters (90% confidence intervals outside the acceptance range). demonstrated, this was not considered to have reduced the usefulness of the statistical model since the study was perCommon side effects attributable to the oral contraceptive
